WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010140824) COMPOSITION FOR DIAGNOSIS AND DETERMINATION OF PROGNOSIS OF HEPATOCELLULAR CARCINOMA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/140824    International Application No.:    PCT/KR2010/003513
Publication Date: 09.12.2010 International Filing Date: 01.06.2010
IPC:
G01N 33/574 (2006.01), C12Q 1/68 (2006.01)
Applicants: INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY [KR/KR]; 664-14, Deokjindong 1-ga Deokjin-gu, Jeonju-si Jeollabuk-do 561-756 (KR) (For All Designated States Except US).
KIM, Dae Ghon [KR/KR]; (KR) (For US Only).
YU, Gyung Ran [KR/KR]; (KR) (For US Only)
Inventors: KIM, Dae Ghon; (KR).
YU, Gyung Ran; (KR)
Priority Data:
10-2009-0048168 01.06.2009 KR
Title (EN) COMPOSITION FOR DIAGNOSIS AND DETERMINATION OF PROGNOSIS OF HEPATOCELLULAR CARCINOMA
(FR) COMPOSITION POUR LE DIAGNOSTIC ET LA DÉTERMINATION DE PRONOSTIC DU CARCINOME HÉPATOCELLULAIRE
(KO) 간세포암의 진단 및 예후결정용 조성물
Abstract: front page image
(EN)The present invention relates to a composition for the diagnosis and determination of the prognosis of hepatocellular carcinoma, and more particularly to a composition for the diagnosis of hepatocellular carcinoma comprising the Ephrine A1 (EFNA1) gene or a protein expressed from the EFNA1 gene and a composition for the determination of the prognosis of hepatocellular carcinoma comprising the EPHA2 gene which is a receptor for EFNA1 or a protein expressed from the EPHA2 gene. The present invention is a marker for diagnosing hepatocellular carcinoma using Ephrine A1 (EFNA1) and its receptor, EPHA2, and can be useful for a biomarker for the diagnosis and determination of the prognosis of hepatocellular carcinoma. The present invention can diagnose hepatocellular carcinoma early by providing the EFNA1 gene and the EPHA2 gene and effectively detecting the expression of a protein which is the EFNA1 gene product in a body fluid. The present invention can quantify the EPHA2 gene expression as a tumor marker in patients' tissues quickly and sensitively and be useful for determining the prognosis of hepatocellular carcinoma progress, that is, the invasive and metastatic potential.
(FR)L'invention concerne une composition pour le diagnostic et la détermination de pronostic du carcinome hépatocellulaire, et plus particulièrement une composition pour le diagnostic du carcinome hépatocellulaire contenant le gène Ephrine A1 (EFNA1) ou une protéine exprimée par le gène EFNA1, et une composition pour la détermination de pronostic du carcinome hépatocellulaire contenant le gène EPHA2 étant un récepteur pour EFNA1 ou une protéine exprimée par le gène EPHA2. L'invention concerne également un marqueur pour le diagnostic du carcinome hépatocellulaire à l'aide d'Ephrine A1 (EFNA1) et de son récepteur EPHA2, pouvant servir de biomarqueur pour le diagnostic et la détermination de pronostic du carcinome hépatocellulaire. L'invention permet un diagnostic précoce du carcinome hépatocellulaire par fourniture du gène EFNA1 et du gène EPHA2 et détection fiable de l'expression d'une protéine étant un produit du gène EFNA1 dans un fluide corporel. L'invention permet de quantifier l'expression du gène EPHA2 en tant que marqueur tumoral dans des tissus de patients de façon rapide et sensible, et peut servir à déterminer le pronostic de la progression du carcinome hépatocellulaire, c'est à dire le potentiel invasif et métastatique.
(KO)본 발명은 간세포암의 진단 및 예후결정용 조성물에 관한 것으로, 보다 구체적으로는 Ephrine A1(EFNA1) 유전자 또는 상기 EFNA1 유전자로부터 발현되는 단백질을 포함하는 것을 특징으로 하는 간세포암 진단용 조성물 및 EFNA1의 수용체인 EPHA2 유전자 또는 상기 EPHA2 유전자로부터 발현되는 단백질을 포함하는 것을 특징으로 하는 간세포암 예후결정용 조성물에 관한 것이다. 본 발명은 Ephrine A1(EFNA1)와 그 수용체인 EPHA2을 이용한 간세포암 진단마커로서 간세포암 진단 및 예후 판정에 유용한 바이오마커로써 이용이 가능하며, EFNA1와 EPHA2 유전자를 제공하고 EFNA1 유전자 산물인 단백질의 발현을 체액에서 효과적으로 검출하여 간세포암을 조기진단하고 EPHA2 유전자 발현을 종양 마커로 환자조직에 신속하고 민감하게 정량하며 간세포암의 진행성, 즉 침습성 및 전이성의 예후를 판단하는데 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)